Literature DB >> 23849895

ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma.

Hunter Johnson1, Ming Zhou, Adeboye O Osunkoya.   

Abstract

TMPRSS2-ERG is the most common gene fusion in conventional prostatic adenocarcinoma (PCa), identified in about 40% to 70% of cases. Mucinous PCa and PCa with mucinous features are rare subtypes of prostate cancer, and ERG expression in these subtypes has not been well characterized in a large series. A search was made through the surgical pathology and expert consultation files of 2 major academic institutions for cases of mucinous PCa and PCa with mucinous features. The former were obtained from radical prostatectomy cases and the latter from radical prostatectomy cases, transurethral resection of the prostate, and prostate needle core biopsies. A tissue microarray composed of additional cases of mucinous PCa was also included in the study. Immunohistochemical stains for ERG were performed on all the cases. A total of 51 cases of mucinous PCa and PCa with mucinous features were identified. Twenty-five of 51 (47%) cases were positive for ERG expression, including 10/24 (42%) radical prostatectomy specimens, 7/14 (50%) biopsies, 2/4 (50%) transurethral resection of the prostate specimens, 6/9 (67%) from a tissue microarray. This is the largest study to date specifically characterizing ERG expression in mucinous PCa and PCa with mucinous features, with emphasis on comparison with adjacent conventional PCa. ERG is expressed in almost 50% of cases of mucinous PCa and PCa with mucinous features, similar to rates of expression in conventional PCa. This study strongly suggests that these rare subtypes of PCa are clonally related to conventional PCa.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conventional prostatic adenocarcinoma; ERG antibody; Mucinous prostatic adenocarcinoma; Prostatic adenocarcinoma with mucinous features; TMPRSS2-ERG

Mesh:

Substances:

Year:  2013        PMID: 23849895     DOI: 10.1016/j.humpath.2013.05.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

2.  Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation.

Authors:  Christos Kalaitzis; Michael Koukourakis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; Efthimios Sivridis; Athanasios Bantis; Stavros Touloupidis
Journal:  Case Rep Urol       Date:  2014-01-29

3.  Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation.

Authors:  Yao Zhang; Hua Shen; Kai Liao; Weili Wu; Jiuming Li; Hongbo Yu; Hongfei Wu; Zengjun Wang
Journal:  Front Oncol       Date:  2020-12-23       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.